Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 145 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Enzalutamide in addition to androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer	Enzalutamide (Xtandi; MDV3100)	Prostate cancer	Male Reproductive Cancer	2019	View \| Download
Entresto for chronic heart failure with preserved ejection fraction	Entresto; LCZ 696 (fixed dose combination: Sacubitril; Valsartan)	Heart failure (HF)	Cardiovascular System	2019	View \| Download
Encorafenib in combination with binimetinib and cetuximab for BRAF V600E mutant metastatic colorectal cancer	Binimetinib (MEK162; MEK-162; ARRY-162) , Cetuximab (Erbitux; STI-001) , Encorafenib (LGX818)	Colorectal cancer	Gastrointestinal Cancer , Oncology	2019	View \| Download
Elexacaftor/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 6 to 11 years old	Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Elexacaftor/tezacaftor/ivacaftor (fixed-dose combination) for cystic fibrosis heterozygous for F508del mutation and one minimal function mutation in patients aged 6 to 11 years	Elexacaftor (VX-445) , Ivacaftor (Kalydeco; VX-770) , Symkevi (fixed dose combination: Tezacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Durvalumab with or without tremelimumab in addition to platinum based chemotherapy for extensive-stage disease small-cell lung cancer	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab in combination with tremelimumab for unresectable hepatocellular carcinoma – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736) , Tremelimumab (CP-675206; CP-675 206)	Hepatocellular carcinoma (HCC)	Gastrointestinal Cancer	2019	View \| Download
Durvalumab in addition to chemotherapy for metastatic non-small-cell lung cancer - first line	Chemotherapy , Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2019	View \| Download
Durvalumab for recurrent or metastatic squamous cell carcinoma of the head and neck – first line	Durvalumab (Imfinzi; MEDI4736; MEDI-4736; MEDI 4736)	Head and neck cancer	Head and Neck Cancer	2019	View \| Download
Dupilumab for children aged 6 to less than 12 years with severe atopic dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2019	View \| Download